Indian CRO

Forecast -

By 2012, analysts project that more than 65 percent of all FDA-regulated trials will take place outside the United States. This is reflected in the Indian biotechnology market, which is expected to grow at a compounded annual growth rate of 30 percent, and the Indian CRO market, which is expected to see growth of 49 percent annually.

Basis-

According to Clinical trials Gov, Currently greater than 50, 000 clinical trials have been registered in North America where the US accounts for around 46,000 of the same. If the above forecast holds true then presuming that all trials are FDA regulated and industry sponsored and outsourced to India, then the market for clinical trials in India would take a market look as follows:

http://blogs.veedacr.com/Lists/Categories/Category.aspx?Name=Indian%20CRO